Livanova Plc · NASDAQ:LIVN

Livanova — Piper Jaffray 30th Annual Healthcare Conference (November 2018)

11 slides from Livanova's conference presentation, Nov 28, 2018

  1. Slide 1: Piper Jaffray 30th Annual Healthcare Conference

    NEUROMODULATION Piper Jaffray 30th Annual Healthcare Conference Heart Valves November 28, 2018 CARDIOVASCULAR

  2. Slide 2: Safe Harbor

    Safe Harbor Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as ame

  3. Slide 3: Intellectual Property

    Intellectual Property This report may contain references to our proprietary intellectual property, including among others: Trademarks for our Neuromodulation systems, the VNS Therapy® System, the VITARIA® System and our proprietary pulse generator products: Model 102 (Pulse®), Model 102R (Pulse Duo®

  4. Slide 4: We are a $1.0B focused medical innovator

    We are a $1.0B¹ focused medical innovator Strong leadership Targeting Improving quality position in underserved and of patients’ lives Neuromodulation high-growth and Cardiovascular market segments 1Full-year 2017 net sales 4

  5. Slide 5: With leading positions in neuromodulation and cardiovascular

    With leading positions in neuromodulation and cardiovascular 3Q18: $272M Cardiopulmonary Drug-Resistant Epilepsy (DRE) 10.3% Growth* 77% (CP) Treatment-Resistant Depression Heart-lung machines (HLM) (TRD) Oxygenators Autotransfusion systems (ATS) Obstructive Sleep Apnea Cannulae (OSA) Advanced Circu

  6. Slide 6: Our portfolio is focused on "Head & Heart"

    Our portfolio is focused on “Head & Heart” CARDIOVASCULAR NEUROMODULATION CARDIOPULMONARY HEART VALVES Creator, leader of VNS Only sutureless valve on Market-leading positions Therapy the market Global Market (2017) $4.1B $3.0B $1.7B Market Growth Low-double-digit Mid-single-digit Low-single-digit S

  7. Slide 7: Multiple near-term growth drivers

    Multiple near-term growth drivers NEUROMODULATION CARDIOVASCULAR Perceval sutureless S5 HLM reduces Inspire oxygenator TandemLife simplifies SenTiva advances valve optimizes the transfusions and provides advanced circulatory the ease-of-use of surgical approach to improves personalized support for c

  8. Slide 8: Differentiated pipeline targeting medical conditions with high unmet needs

    Differentiated pipeline targeting medical conditions with high unmet needs TREATMENT- TRANSCATHETER OBSTRUCTIVE SLEEP RESISTANT MITRAL VALVE HEART FAILURE (HF) APNEA (OSA) DEPRESSION (TRD) REPLACEMENT (TMVR) Novel delivery of VNS Therapy may Implantable pulse Autonomic Regulation provide Unique tran

  9. Slide 9: Full-year 2018 Guidance from Continuing Operations

    Full-year 2018 Guidance from Continuing Operations Reaffirming EPS guidance resulting from improved sales growth, gross margin and tax offset by higher investments in SG&A and R&D Guidance as of Guidance as of May 2, 2018 October 31, 2018 Worldwide net sales growth (1) 6% - 8% 7% - 9% Gross margin (

  10. Slide 10: Accelerating Growth While Investing in our Future

    Accelerating Growth While Investing in our Future • $1B focused medical innovator • Strong leadership position in Neuromodulation and Cardiovascular Performing • Targeting ~$9B global market opportunities • Increasing sales and growing margins • Three acquisitions in the past 18 months – Caisson, Im

  11. Slide 11: LivaNova - Health innovation that matters

    | ivaNova Health innovation that matters uw

LivaNova — Piper Jaffray 30th Annual Healthcare Conference (November 2018) on 6ix